Empower Clinics Inc.
11.8.2021 16:02:21 CEST | ACCESS Newswire | Press release
Strong 2021 Fiscal Performance Supporting Robust Clinic, Testing Expansion and Acquisition Efforts
VANCOUVER, BC / ACCESSWIRE / August 11, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens - is pleased to provide the following corporate update on our national clinic expansion strategy and overview of other corporate endeavors.
"This corporate update is a testament to the growth of Empower Clinics over the last year," said Steven McAuley, Chairman & CEO of Empower. "Our national clinic expansion strategy will provide enhanced access to healthcare for millions of Canadians. We continue to make meaningful strides across our network with various Kai Care testing partnerships and its recent expansion allowing for greater volume and diversification of services. We are also thrilled to have completed the MediSure acquisition and look forward to leveraging our collective network to drive increased volume and new product development."
Clinic Pipelines
The Company is pleased to provide shareholders with an update on its progress of opening new clinics locations that are now in various stages ranging from LOI's, to leases signed, construction underway and opening dates pending.
SIGNED LEASES with construction underway
1) Etobicoke,ON
2) London, ON
3) Etobicoke, ON 2nd flagship location
4) Hamilton, ON
LEASES signed
1) Hamilton, ON Rexall proximity
2) Kitchener, ON Rexall proximity
3) Ajax, ON Rexall proximity
4) Barrie, ON Rexall proximity
PENDING LOI'S & LEASES
1) Sudbury, ON Pharmacy proximity
2) Chatham, ON Pharamcy proximity
3) Nepean, ON Pharmacy proximity
4) Peterborough, ON Pharmacy proximity
5) St. Catherines, ON
Chairman & CEO Mr. McAuley added, "I simply want to say that our Canadian health centre development plan has never been in doubt for us, from the moment we announced the strategy. Working so closely on a plan with pharmacy organizations takes time to materialize, it requires a collective effort with all constituents, but as everyone knows, we have not been idle, we have not been complacent, we have been diligent, respectful and focused on building a long-term strategy. I am so impressed with our business development team and their recruitment of medical doctors to date, that will serve so many communities and neighbourhoods. We seem to be building a collective of healthcare centers, a collective of medical professionals, a collective of knowledge and expertise, focused on the health outcomes of people in the markets we serve."
Acquisitions
Empower Clinics recently finalized the acquisition of leading Canadian diabetic service manufacturing company MediSure. With over $1.9M in revenue for 2020, 50,000 end users and presence in over 4,000 Canadian pharmacies, MediSure represents a highly valuable asset for the Empower Network.
Partnerships
Empower Clinics has signed nine partnership agreements in 2021 with leading companies across Canada and the United States. Each partnership leverages various strengths of the Empower Clinics network. The endeavours include:
- Signed partnership to offer COVID-19 testing on a long-term basis for the Dallas Market Centre
- Signed partnership for select clinics to offer the MedX DermSecure screening platform
- Signed referral agreement with major Canadian airline for Kai Care COVID testing
- Signed partnered with Loop Insights to augment COVID mitigation efforts through testing
- Signed partnership with PharmaChoice to carry Kai Care saliva test kits, Antigen Tests & Antibody Tests in their more than 900 independent pharmacies across Canada
- Signed partnership with Save-On-Foods to sell Kai Saliva tests in Vancouver area stores
- Signed partnership with Tabula Rasa Pharmacy for a dedicated 24-hour customer support line
Financials
Empower Clinics has had a tremendous year of growth that has translated to promising fiscal results. A 58% year-over-year growth and a zero cash loss in 2020 set Empower up to make significant strides in 2021. Empower yielded over $2.5M of revenue in Q1 2021, a 258% growth compared to 2020.
Corporate Talent
Along with tremendous fiscal growth, Empower Clinics is looking to elevate its corporate leadership team and partnerships. Recently retained global executive recruiting firm Korn Ferry has started searching for a new Chief Financial Officer (CFO). An immediate priority for the new executive will be an in-depth review of current financial and audit operations, with the express intent to make recommendations to affect positive change on current practices and partnerships.
This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics
ABOUT EMPOWER:
Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer
CONTACTS:
Investors:
Steven McAuley CEO
s.mcauley@empowerclinics.com
604-789-2146
Investors:
Tamara Mason
Business Development & Communications
t.mason@empowerclinics.com
416-671-5617
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley's franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company's products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion inn 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
SOURCE: Empower Clinics Inc.
View source version on accesswire.com:
https://www.accesswire.com/659317/Empower-Clinics-Provides-Corporate-Update-On-National-Clinic-Expansion
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Iggy Azalea Invests in Shift - The AI Company Behind the Fastest-Growing Platform in the $1.3 Trillion Creator Economy, Fanvue27.8.2026 14:00:00 CEST | Press release
The Grammy-nominated artist and entrepreneur has made a significant investment in SHIFT, whose AI infrastructure has propelled its flagship platform, Fanvue, from a $4m to $200m annualised run rate in just over 2 years. LONDON, UK / ACCESS Newswire / August 27, 2026 / Iggy Azalea, the four-time Grammy-nominated artist, entrepreneur, and active investor, has personally invested a substantial sum in Fanvue's parent company SHIFT - the AI infrastructure the platform runs on. As part of the investment deal, Azalea will also become the founding member of SHIFT's Creator Advisory Board. The move comes at a time when the world's biggest creators, athletes and music artists are increasingly looking to multi-million-dollar equity opportunities in the creator economy - recent examples include MrBeast and the Paul brothers, Jake and Logan. AI is transforming how people make money online. For two decades, the creator economy has run on a simple trade: creators build the audience, and advertisers r
ZAGENO and ORO Labs Partner to Connect Scientific Purchasing with Enterprise Procurement26.8.2026 14:35:00 CEST | Press release
Partnership combines ORO Labs' AI-native procurement orchestration platform with ZAGENO's scientific marketplace and supplier network to deliver a governed, end-to-end purchasing experience for life sciences R&D. BOSTON, MA / ACCESS Newswire / August 26, 2026 / ZAGENO, the scientific procurement platform connecting researchers with 75 million laboratory products from approximately 5,500 suppliers, today announced a strategic partnership with ORO Labs, the AI-native procurement orchestration platform. The partnership connects ORO Labs' enterprise intake, workflow, and approval capabilities with ZAGENO's scientific product discovery, marketplace, supplier network, and fulfillment infrastructure. Together, the companies enable a single governed journey from request and approval through product selection, ordering, and fulfillment. Scientific R&D procurement has specialized requirements. Researchers need fast, intuitive access to highly specific products, while procurement teams need polic
Eudia Accelerates Enterprise AI Transformation with Google Cloud's Gemini Enterprise for Legal25.8.2026 15:50:00 CEST | Press release
PALO ALTO, CA / ACCESS Newswire / August 25, 2026 / Eudia, the augmented intelligence platform for enterprise legal, contracting, and compliance, today announced a partnership with Google to launch new industry-specific AI capabilities on Google Cloud's Gemini Enterprise for Legal. Eudia's agent scales the legal, contracting, and compliance expertise of an organization's top operators to every team in the enterprise. Built on Google's Agent Development Kit and connected via MCP, Eudia combines a suite of specialized agents with digital twins of domain-scoped institutional knowledge, orchestrated with legal-specific reasoning and access to legal databases. Eudia enables Legal, Compliance, Procurement, and Revenue teams to draft and review contracts, analyze marketing assets for compliance, assess risk across thousands of executed contracts, and manage obligations across the entire company portfolio, giving large enterprises a faster path to trusted, governed legal AI. In practice, this
Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth25.8.2026 15:00:00 CEST | Press release
New role unifies sales enablement, lead generation, and marketing under centralized leadership and expands oversight to customer success, supporting a consistent, connected client experience across Envision. FAIRFIELD, CT / ACCESS Newswire / August 25, 2026 / Envision Pharma Group (Envision) has appointed Ryan Tubbs as Senior Vice President, Commercial Growth. In this newly created role, Tubbs will lead the centralized Commercial Growth function spanning sales enablement, lead generation, marketing, and client success. He will also help shape Envision's commercial strategy and operating model to accelerate enterprise growth. Tubbs' remit also includes the Client Implementation and Client Experience teams. Connecting Envision's pre-sale and post-sale capabilities will create a more integrated commercial engine, making it easier for teams to bring the best of Envision to clients and for clients to realize value quickly. The timing is notable as Envision's iEnvision®, market access, and m
Polaris Renewable Energy Announces Renewal of Normal Course Issuer Bid25.8.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / August 25, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") today announced that the Toronto Stock Exchange ("TSX") has accepted its notice of intention to renew its normal course issuer bid ("NCIB"). The Company's Board of Directors believes that an NCIB represents an appropriate and desirable use of its available free cash to increase shareholder value and is in the best interest of the Company and its shareholders. Pursuant to the notice, Polaris may purchase up to 2,021,205 of its common shares ("Shares"), representing approximately 10% of the public float of 20,212,059 Shares as at August 13, 2026, during the twelve month period commencing August 27, 2026 and ending August 26, 2027, provided that the board of directors of Polaris has initially limited the NCIB to repurchase up to 176,872 Shares. As at August 13, 2026, there were 20,895,285 Shares issued and outstanding. Under the NCIB, other than purchases made under block
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
